301 related articles for article (PubMed ID: 24410805)
1. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.
Popova SN; Bergqvist M; Dimberg A; Edqvist PH; Ekman S; Hesselager G; Ponten F; Smits A; Sooman L; Alafuzoff I
Histopathology; 2014 Feb; 64(3):365-79. PubMed ID: 24410805
[TBL] [Abstract][Full Text] [Related]
2. EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis.
Burel-Vandenbos F; Benchetrit M; Miquel C; Fontaine D; Auvergne R; Lebrun-Frenay C; Cardot-Leccia N; Michiels JF; Paquis-Flucklinger V; Virolle T
J Neurooncol; 2011 Apr; 102(2):171-8. PubMed ID: 20652725
[TBL] [Abstract][Full Text] [Related]
3. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
[TBL] [Abstract][Full Text] [Related]
4. Molecular classification of diffuse gliomas.
Jakovlevs A; Vanags A; Gardovskis J; Strumfa I
Pol J Pathol; 2019; 70(4):246-258. PubMed ID: 32146793
[TBL] [Abstract][Full Text] [Related]
5. Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas.
Suzuki A; Nobusawa S; Natsume A; Suzuki H; Kim YH; Yokoo H; Nagaishi M; Ikota H; Nakazawa T; Wakabayashi T; Ohgaki H; Nakazato Y
J Neurooncol; 2014 Nov; 120(2):283-91. PubMed ID: 25085214
[TBL] [Abstract][Full Text] [Related]
6. Lineage-Restricted OLIG2-RTK Signaling Governs the Molecular Subtype of Glioma Stem-like Cells.
Kupp R; Shtayer L; Tien AC; Szeto E; Sanai N; Rowitch DH; Mehta S
Cell Rep; 2016 Sep; 16(11):2838-2845. PubMed ID: 27626655
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping.
Higgins RJ; Dickinson PJ; LeCouteur RA; Bollen AW; Wang H; Wang H; Corely LJ; Moore LM; Zang W; Fuller GN
J Neurooncol; 2010 May; 98(1):49-55. PubMed ID: 19967449
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: a multi-institutional analysis of 941 cases.
Lin N; Yan W; Gao K; Wang Y; Zhang J; You Y
PLoS One; 2014; 9(4):e94871. PubMed ID: 24755548
[TBL] [Abstract][Full Text] [Related]
9. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
[TBL] [Abstract][Full Text] [Related]
10. Utility of combining OLIG2 and SOX10 IHC expression in CNS tumours: promising biomarkers for subtyping paediatric- and adult-type gliomas.
Aboubakr O; Métais A; Maillard J; Hasty L; Brigot E; Berthaud C; Lacombe J; Pucelle N; Raynal J; Appay R; Varlet P; Tauziède-Espariat A
Histopathology; 2024 Apr; 84(5):893-899. PubMed ID: 38253970
[TBL] [Abstract][Full Text] [Related]
11. Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation.
Azar S; Leventoux N; Ripoll C; Rigau V; Gozé C; Lorcy F; Bauchet L; Duffau H; Guichet PO; Rothhut B; Hugnot JP
Glia; 2018 Feb; 66(2):239-255. PubMed ID: 29027701
[TBL] [Abstract][Full Text] [Related]
12. Molecular subtypes of glioblastoma are relevant to lower grade glioma.
Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS
PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
Sipayya V; Sharma I; Sharma KC; Singh A
J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
[TBL] [Abstract][Full Text] [Related]
14. A simplified approach for the molecular classification of glioblastomas.
Le Mercier M; Hastir D; Moles Lopez X; De Nève N; Maris C; Trepant AL; Rorive S; Decaestecker C; Salmon I
PLoS One; 2012; 7(9):e45475. PubMed ID: 23029035
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Prognosis of High-Grade gliomas in the View of New Immunohistochemistry Markers and 2016 WHO Classification.
Dolen D; Ahmadov T; Dolas I; Unal TC; Aydoseli A; Ozturk M; Sabanci PA; Aras Y; Bilgic MB; Sencer A
Turk Neurosurg; 2022; 32(3):500-507. PubMed ID: 35615769
[TBL] [Abstract][Full Text] [Related]
16. Correlation between deregulated expression of PER2 gene and degree of glioma malignancy.
Wang F; Luo Y; Li C; Chen L
Tumori; 2014; 100(6):e266-72. PubMed ID: 25688509
[TBL] [Abstract][Full Text] [Related]
17. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.
Mokhtari K; Paris S; Aguirre-Cruz L; Privat N; Crinière E; Marie Y; Hauw JJ; Kujas M; Rowitch D; Hoang-Xuan K; Delattre JY; Sanson M
Neuropathol Appl Neurobiol; 2005 Feb; 31(1):62-9. PubMed ID: 15634232
[TBL] [Abstract][Full Text] [Related]
18. The clinical value of proneural, classical and mesenchymal protein signatures in WHO 2021 adult-type diffuse lower-grade gliomas.
Dénes A; Bontell TO; Barchéus H; Vega SF; Carén H; Lindskog C; Jakola AS; Smits A
PLoS One; 2023; 18(5):e0285732. PubMed ID: 37192181
[TBL] [Abstract][Full Text] [Related]
19. Experimental validation of 5 in-silico predicted glioma biomarkers.
Towner RA; Jensen RL; Vaillant B; Colman H; Saunders D; Giles CB; Wren JD
Neuro Oncol; 2013 Dec; 15(12):1625-34. PubMed ID: 24158112
[TBL] [Abstract][Full Text] [Related]
20. Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas.
Li JY; Wang H; May S; Song X; Fueyo J; Fuller GN; Wang H
J Neurooncol; 2008 May; 88(1):11-7. PubMed ID: 18246408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
